Is a test of cure necessary following treatment for cervical infection with *Chlamydia trachomatis*?

K W Radcliffe, D Rowen, D E Mercey, G Mumtaz, G L Ridgway, A J Robinson, J S Bingham

Abstract
Tests of cure (TOC) were performed on specimens from 106 women following treatment for chlamydial infection of the cervix. 91 women attended for the first TOC with enzyme immunoassay (EIA) within one week of finishing antibiotics. Three were EIA positive, 88 were EIA negative. These three women were subsequently EIA and culture negative although they received no further antibiotics. Ninety women returned for the second TOC with EIA and culture between seven and 27 days after completing treatment. All the results were negative. Routine TOC is unnecessary following appropriate antichlamydial therapy. If TOC is indicated antigen-detection methods should not be used immediately after finishing antibiotics as misleading positive results may be obtained. EIA or culture at one week or later after treatment is reliable.

Introduction
Infection of the lower genital tract with *Chlamydia trachomatis* is one of the commonest sexually transmitted diseases. It is common clinical practice following treatment to repeat microbiological tests to ensure chlamydiae have been eradicated. This study was undertaken to investigate whether such a test of cure (TOC) is necessary and if so whether enzyme immunoassay (EIA) or cell-culture is the more appropriate test and how long after completion of treatment it should be done.

Patients and methods
Female patients attending the departments of Genitourinary Medicine at the Middlesex and University College Hospitals who had positive cervical cultures for *C. trachomatis* were recruited into the study.

Suitable patients were identified in two ways:

1. Women attending the departments were screened for chlamydiae by EIA (Chlamydiazyme, Abbott Laboratories). Women with positive EIA had cultures taken prior to treatment;

2. Women attending as contacts of men with nongonococcal urethritis (NGU) had cultures taken before receiving antibiotics.

Informed consent was obtained from all subjects. Treatment prescribed was either doxycycline 100 mg twice a day or oxytetracycline 500 mg four times a day, for seven days.

Subjects were advised to abstain from intercourse until cure was established. They were asked to return the day after finishing antibiotics for TOC with EIA and after a further seven days for a second TOC with EIA and culture. Women attending more than seven days after completing treatment were excluded from analysis of the first TOC.

Specimens for EIA were collected, transported and examined according to the manufacturer's recommendations. Positive results were confirmed by a specific blocking antibody test. Specimens giving equivocal results were further examined by direct immunofluorescence (Microtrak, Syva Company) of the EIA buffer as described in a previous study.1

Specimens for culture were obtained from the endocervical canal using cotton-wool tipped swabs after the ectocervix had been wiped with a cotton-wool ball. Specimens were transported to the laboratory in 2-sucrose phosphate medium and inoculated onto duplicate monolayers of cycloheximide-treated McCoy cells. After incubation for 48 to 72 hours one culture was fixed, stained with iodeine and examined for typical inclusions. If no chlamydiae were detected the second culture was passaged onto fresh McCoy cells and after a further 48 to 72 hours incubation was examined by direct immunofluorescence (Syva Microtrak *C. trachomatis* Culture Confirmation Test).

Results
One hundred and six women returned for one or both TOC. Culture was positive prior to treatment in 105. One was culture-negative but positive to both EIA
Discussion

In this study, microbiological cure was established in all 90 women who returned for the final TOC. This is consistent with the following laboratory and clinical evidence, which indicates that antichlamydial therapy is extremely effective unless there is non-compliance or the patient is reinfected.

In vitro assays show C. trachomatis to be highly susceptible to the tetracyclines and erythromycin. Naturally occurring resistance of chlamydiae to these antibiotics has never been described.

In the largest series of women followed after treatment for cervical infection with C. trachomatis, 161 women were examined repeatedly for up to 20 months after taking oxytetracycline 250 mg four times a day for 21 days. Chlamydiae were detected by culture in 16 (10%) patients at these times. However, 10 of these women had current partners with proven gonorrhoea, NGU or chlamydial infection, and the remaining six were all having intercourse with the original or a new partner. Therefore, reinfection and not treatment failure was the probable explanation for the re-isolation of chlamydiae in all cases.

Erythromycin has been shown to be as effective as oxytetracycline in the treatment of cervical infection with C. trachomatis.

The results of this present study indicate that routine TOC following therapy for cervical chlamydial infection is unnecessary. This accords with the advice of both the Centers for Disease Control and the World Health Organisation.

Clinical follow-up will still be necessary in the majority of cases: to assess compliance, to exclude possible reinfecion, to exclude adverse effects of antibiotics and for further contact tracing. The physician may feel that a TOC is indicated in cases where non-compliance or reinfection is suspected.

If a TOC is required, an antigen-detection method should not be used immediately after finishing treatment. Both EIA and DFA can give misleading positive results in this situation owing to the detection of persisting antigens from non-viable chlamydiae. This is the probable explanation of the positive EIA results in the three women (3.3%) in this study who were subsequently EIA and culture negative. In a similar study comparing EIA and culture as TOC one subject (4%) was EIA positive but culture negative on the seventh (and final) day of therapy with erythromycin but was EIA and culture negative one week later. Another study by Nachamkin et al. evaluated DFA as TOC and found that 7/38 (18%) patients gave borderline results seven to ten days after the completion of treatment.

Patients who have just completed a course of antichlamydial therapy will have a low prevalence of C. trachomatis. The results of antigen-detection tests have lower positive predictive values in low-prevalence populations and less confidence could be placed in a positive result in such circumstances.

Use of cell-culture immediately after cessation of treatment would also be inadvisable as sufficient antibiotic may be present to inhibit growth of chlamydiae.

The results of this study indicate that EIA or culture is reliable for TOC when performed one week or later after finishing therapy. This is consistent with the results of Lefevre et al. who found 100% correlation between EIA, culture and DFA when used for TOC four weeks or longer after treatment. Further studies are necessary to elucidate whether DFA is suitable for TOC performed earlier than four weeks.

In summary, TOC is not necessary following appropriate antichlamydial therapy unless non-compliance or reinfection is suspected. If the clinician believes TOC is indicated EIA or culture should be taken one week or later after finishing antibiotics.

Address for correspondence: Dr K W Radcliffe, Department of Genitourinary Medicine, Charing Cross Hospital, London W6 8RF, UK.


8 Kellogg JA. Clinical and laboratory considerations of culture vs antigen assays for detection of *Chlamydia trachomatis* from genital specimens. *Arch Pathol Lab Med* 1989;113:453-60.


Accepted for publication 17 September 1990.
Is a test of cure necessary following treatment for cervical infection with Chlamydia trachomatis?
K W Radcliffe, D Rowen, D E Mercey, G Mumtaz, G L Ridgway, A J Robinson and J S Bingham

*Genitourin Med* 1990 66: 444-446
doi: 10.1136/sti.66.6.444

Updated information and services can be found at:
http://sti.bmj.com/content/66/6/444

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/